



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 01-1023-G)

In re Application of:

B. Frank et al

Serial No.: 08/901,612

Filed: July 28, 1997

For: Oligonucleotides Specific for Hepatitis  
B Virus

Asst. Commissioner for Patents  
Washington, DC 20231

) Group Art Unit: 1635

) Examiner: T. Larson

# 41 / K.T.  
1/25

F

RECEIVED

JAN 22 2002

TECH CENTER 1600/2900

**AMENDMENT AND RESPONSE TO THE JUNE 01, 2001 OFFICE ACTION**

In response to the Office Action mailed June 1, 2001, please enter the following amendment and consider the following remarks.

**AMENDMENT**

In the Claims:

A marked-up version of the following amended claims is attached as Appendix A.

A clean copy of all the pending claims is attached as Appendix B.

Please amend claims 1, 8-20, 36 and 47 as follows:

1. A synthetic oligonucleotide complementary to a portion of the epsilon region of the HBV genome selected from the group consisting of SEQ ID NOS: 7-19 and 45, which oligonucleotide inhibits HBV replication.

8. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 7.

*F2*  
CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this document is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 30 day of October, 2001.

*Jill Awane*